Childhood survivors of high-risk neuroblastoma show signs of immune recovery and not immunosenescence

Warning

This publication doesn't include Faculty of Economics and Administration. It includes Faculty of Medicine. Official publication website can be found on muni.cz.

Authors	LÁZNIČKOVÁ Petra KEPÁK Tomáš HORTOVÁ KOHOUTKOVÁ Marcela HORVÁTH Luděk SHEARDOVÁ Kateřina MARCINIAK Rafał VACCA Carmine SIKLOVA Michaela ZELANTE Teresa ROSSMEISLOVA Lenka KŘENOVÁ Zdenka ŠTĚRBA Jaroslav BENDICKOVA Kamila FRIČ Jan
Year of publication	2020
Type	Article in Periodical
Magazine / Source	EUROPEAN JOURNAL OF IMMUNOLOGY
MU Faculty or unit	Faculty of Medicine
Citation
Web	https://onlinelibrary.wiley.com/doi/full/10.1002/eji.202048541
Doi	http://dx.doi.org/10.1002/eji.202048541
Keywords	adverse late effects; childhood; immune recovery; immunosenescence; neuroblastoma
Description	Neuroblastoma survivors show signs of immunosenescence early after therapy in CD8(+)T cell compartment and elevated plasma TNF-alpha but in later follow-up immune recovery comes into play. Whether the recovery phenotype is long lasting or transient remains to be elucidated, however, late adverse effects often occur in childhood cancer survivors.
Related projects:	Personalizovaná léčba v dětské onkologii: na cestě k "liquid dynamic medicine" a "N-of-1 clinical trials"